Hella Kohlhof PhD

Dr. Hella Kohlhof joined Immunic in January 2017 from 4SC AG, a publicly listed German biotech company where she was responsible for the management of the clinical product portfolio. Dr. Kohlhof also serves as Managing Director of Immunic’s research subsidiary, Immunic Research GmbH, Halle (Saale). She brings to Immunic a very strong scientific background in the immunology and oncology field and is experienced in drug development, preclinical and translational pharmacology.

In 2008, Dr. Kohlhof joined 4SC AG as a research scientist and group leader and established the research laboratory for translational pharmacology. She worked on 4SC’s preclinical and clinical stage projects including IMU-838 and IMU-935. From 2011 to 2015, Dr. Kohlhof was responsible for the management and development of 4SC’s epigenetic clinical-stage small molecule inhibitor 4SC-202. In 2015, Dr. Kohlhof was named Director, Development Projects, and assumed responsibility for the entire product development pipeline of 4SC including clinical trial design and biomarker development.

Dr. Kohlhof studied biology in Aachen and Munich, Germany, and Gothenburg, Sweden, and received her doctorate in biology from the Ludwig Maximilians University of Munich. She performed her post-doctorate work at the Institute of Clinical Molecular Biology and Tumor Genetics at the Helmholtz Centre in Munich, where she worked on normal and malignant B cell development influenced by Notch and Epstein Barr Virus-mediated signaling. Dr. Kohlhof has been awarded several patents and is a co-author of several scientific publications. She is a frequent guest speaker at scientific and industry conferences.